Cassava Sciences to Present at H.C. Wainwright’s 21st Annual Global Investment Conference
September 03 2019 - 8:30AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company, announced today that Remi Barbier, President
& CEO, will present a corporate and clinical overview at H.C.
Wainwright’s 21st Annual Global Investment Conference.
Event details follow:
Date: |
Monday,
September 9th |
Time: |
4:15 p.m. Eastern Time |
Place: |
Lotte New York Palace Hotel (455 Madison Avenue at 50th
Street) |
Webcast: |
https://www.CassavaSciences.com/company-presentations |
Cassava Sciences’ public presentation can be
followed live via webcast. It will also be available for replay for
90 days following the conference on CassavaSciences.com in the
‘Investors’ section.
We recently concluded a Phase 2a clinical study
with PTI-125 in patients with Alzheimer’s disease. In Q3 2019, we
expect to announce top-line results of this study.
PTI-125 is our drug candidate for Alzheimer’s
disease. PTI-125 has a novel mechanism of action: it stabilizes a
critical, and misfolded, protein in the brain. This has the dual
effect of suppressing neurodegeneration and neuroinflammation. In
published studies, PTI-125 has demonstrated slowing of disease
progression in animal models of disease
About Cassava Sciences’ Phase 2a
StudyWe recently concluded a Phase 2a study with PTI-125
in patients with Alzheimer’s disease, funded by a research grant
from the National Institutes of Health (NIH). An objective of this
first-in-patient study was to investigate the effects of PTI-125 on
biomarkers of Alzheimer’s pathology, neurodegeneration and
neuroinflammation. Biomarkers reflect fundamental biochemical
changes in the Alzheimer’s brain and include tau; neurofilament
light chain (NfL); neurogranin; YKL-40; interleukin 6 (IL-6);
interleukin 1 beta (IL-1B); tumor necrosis factor alpha (TNFa);
amyloid beta; and others. Our Phase 2a was a U.S., multi-center,
open-label study of PTI-125 in thirteen patients with
mild-to-moderate Alzheimer’s disease. Study patients received
PTI-125 100 mg twice-daily for 28 days. Cerebrospinal fluid (CSF)
was drawn from patients before treatment and after 28 days of
treatment with PTI-125. Biomarkers were then measured in CSF, and
levels were compared before and after drug treatment.
Our Scientific ApproachThe
target of PTI-125 is an altered form of filamin A (FLNA), a
scaffolding protein. Altered FLNA in the brain disrupts the
normal function of neurons, leading to Alzheimer’s pathology,
neurodegeneration and inflammation. Our investigational drug
candidate, PTI-125, restores the normal shape of FLNA in the brain.
This stabilizes the normal function of certain brain receptors and
exerts powerful anti-neuroinflammatory effects.
We are also developing a biomarker/diagnostic to
detect Alzheimer’s disease with a simple blood test. This program,
called PTI-125Dx, also receives scientific and financial support
from NIH.
The underlying science for our programs in
neurodegeneration is published in several prestigious peer-reviewed
technical journals, including Journal of Neuroscience, Neurobiology
of Aging, and Journal of Biological Chemistry. As previously
announced, NIH awarded us two research grants in 2018 following an
in-depth, confidential review of our science and technology.
These two NIH grants represent up to $6.7 million of non-dilutive
financing.
About Alzheimer's
DiseaseAlzheimer’s disease is a progressive brain disorder
that destroys memory and thinking skills. Eventually, a person with
Alzheimer’s disease may be unable to carry out even simple tasks.
Currently, there are no drug therapies to halt Alzheimer’s disease,
much less reverse its course. Unless effective treatments are
developed soon, Alzheimer’s disease is likely to become one of the
world’s most serious health care crises.
About Cassava Sciences,
Inc.The mission of Cassava Sciences is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Over the
past ten years, we have combined state-of-the-art technology with
new insights in neurobiology to develop novel solutions for
Alzheimer’s disease. We own worldwide development and commercial
rights to our research programs in Alzheimer’s disease, and related
technology, without royalty obligations to any third-party.
For More Information
Contact:Eric Schoen, Chief Financial OfficerCassava
Sciences, Inc.eschoen@CassavaSciences.com(512) 501-2450
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cassava Sciences disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the timing of
clinical studies and study data and the potential benefits of the
Company’s programs in Alzheimer’s disease, including its ongoing
Phase 2 program. The Company cautions that forward-looking
statements are inherently uncertain. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factors. Such statements involve risks
and uncertainties, including, but not limited to, those risks and
uncertainties relating to the ability to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates and including those described in the section
entitled “Risk Factors” in Cassava’s Annual Report on Form 10-K for
the year ended December 31, 2018. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. Except as required by law, the Company disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release.
For further information regarding these and other risks related to
our business, investors should consult our filings with the U.S.
Securities and Exchange Commission (SEC), which are available on
the SEC's website at www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024